RxKinetix starts Phase II oral mucositis trial

RxKinetix (Louisville, Colo.) started a U.S. Phase II trial of its RK-0202 small molecule antioxidant to treat oral mucositis in 100 patients undergoing radiotherapy for head and neck cancer. The endp...